Imperial College London
Alternate

Professor Neil Poulter

Faculty of Medicine, School of Public Health

Professor of Preventive Cardiovascular Medicine.
 
 
 
//

Contact

 

+44 (0)20 7594 3446n.poulter

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

55Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Zinman:2017:10.1007/s00125-017-4423-z,
author = {Zinman, B and Marso, SP and Poulter, NR and Emerson, SS and Pieber, TR and Pratley, RE and Lange, M and Brown-Frandsen, K and Moses, A and Ocampo, Francisco AM and Barner, Lekdrof J and Kvist, K and Buse, JB and DEVOTE, Study Group},
doi = {10.1007/s00125-017-4423-z},
journal = {Diabetologia},
pages = {48--57},
title = {Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)},
url = {http://dx.doi.org/10.1007/s00125-017-4423-z},
volume = {61},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Aims/hypothesisThe Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was a double-blind, randomised, event-driven, treat-to-target prospective trial comparing the cardiovascular safety of insulin degludec with that of insulin glargine U100 (100 units/ml) in patients with type 2 diabetes at high risk of cardiovascular events. This paper reports a secondary analysis investigating associations of day-to-day fasting glycaemic variability (pre-breakfast self-measured blood glucose [SMBG]) with severe hypoglycaemia and cardiovascular outcomes.MethodsIn DEVOTE, patients with type 2 diabetes were randomised to receive insulin degludec or insulin glargine U100 once daily. The primary outcome was the first occurrence of an adjudicated major adverse cardiovascular event (MACE). Adjudicated severe hypoglycaemia was the pre-specified secondary outcome. In this article, day-to-day fasting glycaemic variability was based on the standard deviation of the pre-breakfast SMBG measurements. The variability measure was calculated as follows. Each month, only the three pre-breakfast SMBG measurements recorded before contact with the site were used to determine a day-to-day fasting glycaemic variability measure for each patient. For each patient, the variance of the three log-transformed pre-breakfast SMBG measurements each month was determined. The standard deviation was determined as the square root of the mean of these monthly variances and was defined as day-to-day fasting glycaemic variability. The associations between day-to-day fasting glycaemic variability and severe hypoglycaemia, MACE and all-cause mortality were analysed for the pooled trial population with Cox proportional hazards models. Several sensitivity analyses were conducted, including adjustments for baseline characteristics and most recent HbA1c.ResultsDay-to-day fasting glycaemic variability was significantly a
AU  - Zinman,B
AU  - Marso,SP
AU  - Poulter,NR
AU  - Emerson,SS
AU  - Pieber,TR
AU  - Pratley,RE
AU  - Lange,M
AU  - Brown-Frandsen,K
AU  - Moses,A
AU  - Ocampo,Francisco AM
AU  - Barner,Lekdrof J
AU  - Kvist,K
AU  - Buse,JB
AU  - DEVOTE,Study Group
DO  - 10.1007/s00125-017-4423-z
EP  - 57
PY  - 2017///
SN  - 0012-186X
SP  - 48
TI  - Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
T2  - Diabetologia
UR  - http://dx.doi.org/10.1007/s00125-017-4423-z
UR  - http://hdl.handle.net/10044/1/50409
VL  - 61
ER  -
Download